873581-32-9

Upstream product

• 16948-16-6 N-(tert-butoxycarbonyl)-N-methyl-L-alanine 
• 1514923-26-2 methyl ((S)-2-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propanamido)-2-cyclohexylacetyl)-L-prolinate 
• 894789-27-6 (2S)-2-[(2S)-2-[[(tert-butoxy)carbonyl](methyl)amino]propanamido]-2-cyclohexylacetic acid 
• 912338-14-8 methyl (2S)-2-[(2S)-2-{[(tert-butoxy)carbonyl](methyl)amino}propanamido]-2-cyclohexylacetate 
• 873581-17-0 (2S)-1-[(2S)-2-[(2S)-2-[[(tert-butoxy)carbonyl](methyl)amino]propanamido]-2-cyclohexylacetyl]pyrrolidine-2-carboxylic acid 

Downstream Products

• 873581-49-8 tert-butyl ((S)-1-(((S)-2-((S)-2-((2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-phenylthiazol-5-yl)carbamoyl)pyrrolidin-1-yl)-1-cyclohexyl-2-oxoethyl)amino)-1-oxopropan-2-yl)(methyl)carbamate 

Relevant academic research and scientific papers

CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE

The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.

INHIBITORS OF IAP

Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula (I): wherein R1,R2,R3,R4,R5 and R6 are as described herein.

INHIBITORS OF IAP

The invention provides novel compounds that are inhibitors of IAPs having the general formula: wherein X1, X2, X3, Y, A, R1, R2, R3, R4, R4', R5, R5'/

Inhibitors of IAP

The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein X, Y, A, R1, R2, R3, R4, R4′, R5, R5′, R6 and R6′ are as described herein.